A Prospective Multicenter, Double-Masked, Randomized, Parallel-Group, Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI (Axitinib Implant) for Intravitreal Use in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
Latest Information Update: 06 Sep 2024
At a glance
- Drugs Axitinib (Primary) ; Aflibercept
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Ocular Therapeutix
- 05 Sep 2024 According to an Ocular Therapeutix media release, data from the study will be presented at retina meetings being held in Portugal and Spain in September 2024.
- 25 Jan 2024 Status changed from active, no longer recruiting to completed.
- 03 Oct 2023 According to an Ocular Therapeutix media release, the pivotal trial was initiated based on the previously announced positive 12-month top-line data from the Companys 21-subject U.S.-based Phase 1 trial of OTX-TKI for the treatment of wet AMD